Legal News Watch - Consumer Rights Blog

Entries from April 2005

Securities Class Action Lawsuit Against GSK Over Paxil

April 18th, 2005 · No Comments

A lawsuit seeking class action status has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons who purchased the publicly traded securities of GlaxoSmithKline plc between February 21, 2001 and August 5, 2004 (the “Class Period”).
The lawsuit, filed by the law firm of Schatz & […]

Tags: Paxil

LexisNexis Breach Jeopardizes Idenity of Nearly 310,000 Americans

April 13th, 2005 · No Comments

Personal information on as many as 310,000 U.S. citizens - including Social Security numbers (SSN) or Driver’s License numbers (DLN), may have been stolen from a LexisNexis database, publisher and data broker Reed Elsevier Group PLC said Tuesday. The figure is 10 times more than LexisNexis’s initial estimate last month.
The company said an analysis of […]

Tags: Uncategorized

Bextra Lawsuits Filed Against Pfizer in New York

April 11th, 2005 · 11 Comments

Three Bextra lawsuits were filed against Pfizer Inc. on behalf of three individuals who allegedly were injured by the pain relief drug, Bextra, the Philadelphia law firm Kline & Specter, P.C. announced Monday in a statement.
Two of the plaintiffs suffered heart attacks and one sustained a stroke after taking Bextra, attorneys for the plaintiffs stated.
Pfizer, […]

Tags: Bextra

Chicago Law Firm Files Bextra Class Action Lawsuit Against Pfizer

April 11th, 2005 · 4 Comments

A class action lawsuit was filed against Pfizer Inc., on behalf of all persons who died or were injured by the pain relief drug, Bextra, the Chicago law firm Kenneth B. Moll & Associates, Ltd. announced Monday.
The Bextra lawsuit accuses pharmaceutical giant Pfizer of failing to properly research the known risks of Bextra, warn consumers […]

Tags: Bextra

Attorneys Request Bextra Lawsuits be Transferred to Louisiana

April 8th, 2005 · No Comments

Pfizer Inc., the world’s largest drug maker, said Thursday it would remove the arthritis drug Bextra from the market. Following yesterday’s announcement, Louisiana attorneys for Bextra and Celebrex patients asked today a judicial panel in Washington, D.C. to move all Bextra and Celebrex lawsuits in the country to one federal court, the U.S. District Court […]

Tags: Bextra

Celebrex to Include Boxed Warning, FDA Says

April 8th, 2005 · No Comments

Celebrex, a pain relief drug from Pfizer Inc., will include a boxed warning, highlighting the potential for increased risk of heart problems and the serious, potential life-threatening gastrointestinal (GI) bleeding associated with its use, the Food and Drug Administration said Thursday in a statement.
The agency is asking manufacturers of all prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), […]

Tags: Celebrex

Bextra Pulled From Market in U.S. and Europe, Pfizer Says

April 7th, 2005 · No Comments

Bextra, the pain relief drug from Pifzer Inc., was taken off the market Thursday because the overall risk versus benefit profile for Bextra is “unfavorable,” the Food and Drug Administration said.
Bextra belongs to a class of drugs called Cox-2 inhibitors, including Celebrex (made by Pfizer) and Vioxx (made by Merck & Company). All three painkillers […]

Tags: Bextra

Public Citizen Calls on FDA to Ban Cylert Over Liver Toxcity Risk

April 5th, 2005 · 1 Comment

Cylert or pemoline, made by Abbott Laboratories, for the treatment of attention deficit hyperactive disorder (ADHD) should be taken off the market immediately because of its risk of liver toxicity, a consumer advocay group wrote in a petition to the Food and Drug Administration.
At least 21 cases of liver failure, including 13 resulting in liver […]

Tags: Cylert

Blockbuster Settles ‘No Late Fees’ (’End of Late Fees’) Claims

April 4th, 2005 · No Comments

Blockbuster Inc. has agreed to pay $630,000 to settle claims by 47 states that said it misled consumers in advertising its “End of Late Fees” or “No Late Fees” program, California’s Attorney General Bill Lockyer said Tuesday.
“Blockbuster’s No Late Fees campaign may have had a catchy slogan and clever ads, but it did not tell […]

Tags: Deceptive Advertising

Remeron Settlement Results in $36 Million for Consumers

April 4th, 2005 · 3 Comments

Thousands of consumers nationwide who purchased the antidepressant drug Remeron or its generic equivalent, mirtazapine, may get cash back based on their out-of-pocket expenses.
The cash recovery is a result of a $36 million nationwide settlement with drug maker Organon USA Inc. and its parent company Akzo Nobel N.V. for allegedly improperly monopolizing the U.S. market […]

Tags: Remeron